DOI: https://dx.doi.org/10.18565/pharmateca.2021.4.99-104
И.А. Барсуков, А.А. Демина
Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского, Москва, Россия
1. Chow N., Shearer D., Tildesley H.G., et al. Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods. BMJ. Open Diab Res Care. 2016;4(1):e000145. Doi: 10.1136/bmjdrc-2015-000145. 2. Bruttomesso D., Costa S., Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diab Metab Res Rev. 2009;25:99–111. Doi: 10.1002/dmrr.931. 3. Reznik Y., Cohen O., Aronson R., et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial. Lancet. 2014;384:1265–72. Doi: 10.1016/S0140-6736(14)61037-0. 4. Pickup J., Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324(7339):705. Doi: 10.1136/bmj.324.7339.705. 5. Дедов И.И., Шестакова М.В. Сахарный диабет типа 1: реалии и перспективы. М., 2016. 504 с. 6. Bode B.W., Davidson P.C., Fredrickson L.P., et al. Diabetes management in the new millennium using insulin pump therapy. Diab Metab Res Rev. 2002;18(Suppl. 1):S14–20. Doi: 10.1002/dmrr.205. 7. Hoogma R.P., Hammond P.J., Gomis R., et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diab Med. 2006;23(2):141–47. Doi: 10.1111/j.1464-5491.2005.01738.x. 8. Luijf Y.M., van Bon A.C., Hoekstra J.B., et al. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diab Care 2010;33:2152–55. Doi: 10.2337/dc10-0692. 9. Lilly E. Humalog (insulin lispro): Summary of Product Characteristics 10. Novo Nordisk. NovoRapid (insulin aspart): Summary of Product Characteristics 11. Sanofi-aventis. Apidra (insulin glulisine): Summary of Product Characteristics 12. Owens D.R., Zinman B., Bolli G.B. Insulins today and beyond. Lancet. 2001;358:739–46. Doi: 10.1016/S0140-6736(01)05842-1. 13. Cobry E., McFann K., Messer L., et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diab Technol Ther. 2010;12:173–77. Doi: 10.1089/dia.2009.0112. 14. Scaramuzza A.E., Iafusco D., Santoro L., et al. Timing of bolus in children with type 1 diabetes using continuous subcutaneous insulin infusion (TiBoDi Study). Diab Technol Ther. 2010;12:149–52. Doi: 10.1089/dia.2009.0117. 15. Heinemann L., Muchmore D.B. Ultrafast-acting insulins: state of the art. J Diab Sci Technol. 2012;6:728–42. Doi: 10.1177/193229681200600402. 16. James M.L., Green L., Amiel S.A., et al. Evaluation of the effect of carbohydrate intake on postprandial glucose in patients with type 1 diabetes treated with insulin pumps. J Diab Sci Technol. 2016. Doi: 10.1177/1932296816646797. 17. El-Khatib F.H., Russell S.J., Nathan D.M., et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2:27ra27. Doi: 10.1126/scitranslmed.3000619. 18. Luijf Y.M., DeVries J.H., Zwinderman K., et al. Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient selfmanagement. Diab Care 2013;36:3882–87. Doi: 10.2337/dc12-1956. 19. Russell S.J., El-Khatib F.H., Nathan D.M., et al. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diab Care 2012;35:2148–55. Doi: 10.2337/dc12-0071. 20. Bode B.W., Johnson J.A., Hyveled L., et al. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. Diab Technol Ther. 2017;19(1):25–33. Doi: 10.1089/dia.2016.0350. 21. Heise T., Pieber T.R., Danne T., et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56(5):551–59. Doi: 10.1007/s40262-017-0514-8. 22. Russell-Jones D., Bode B.W., De Block C., et al. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diab Care. 2017;40(7):943–50. Doi: 10.2337/dc16-1771. 23. Bowering K., Case C., Harvey J., Reeves M., et al. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diab Care. 2017;40(7):951–57. Doi: 10.2337/dc16-1770. 24. Klonoff D.C., Evans M.L., Lane W., et al. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diab Obes Metab. 2019;21(4):961–67. Doi: 10.1111/dom.13610. 25. Fiasp (insulin aspart) prescribing information. Bagsvaerd: Novo Nordisk; 2017. 26. Fath M., Danne T., Biester T., et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diab. 2017;18:903–10. Doi: 10.1111/pedi.12506. 27. Battelino T., Danne T., Bergenstal R.M., et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diab Care. 2019;42(8):1593–603. Doi: 10.2337/dci19-0028.
Автор для связи: И.А. Барсуков, к.м.н., старший науч. сотр. отделения терапевтической эндокринологии, МОНИКИ им. М.Ф. Владимирского, Москва, Россия; palantirr@inbox.ru ORCID:
Адрес: 129110, Россия, Москва, ул. Щепкина, 61/2
И.А. Барсуков, https://orcid.org/0000-0002-1889-8555
А.А. Демина, https://orcid.org/0000-0002-7742-5782